recombinant anti-ki67 antibody Search Results


anti ki67  (Danaher Inc)
95
Danaher Inc anti ki67
Silencing of TRPM2-AS inhibited NSCLC progression in vivo. After injection with transfected A549 cells, the mice were observed every 5 days and sacrificed on day 30. (A) The tumors were harvested on day 30. (B) The tumor volume was measured and analyzed with one-way analysis of variance. (C) Relative TRPM2-AS and miR-138-5p expression in xenograft tumors was tested by qRT-PCR. (D) Expression levels of EGFR, <t>Ki67,</t> and TUNEL in the xenograft tumors were detected with immunohistochemistry under 200× scope (stained with diaminobenzidine). (E) Relative EGFR expression in the xenograft tumors. (F) Relative miR-138-5p expression in the xenograft tumors was tested by qRT-PCR. (G) Cell apoptosis in the xenograft tumors was tested with TUNEL assay. The staining was analyzed with Image Pro Plus. Data are shown as mean ± SD. *, P<0.05, **, P<0.01 versus control t-test or one-way ANOVA. NSCLC, non-small cell lung cancer; qRT-PCR, quantitative real-time polymerase chain reaction; EGFR, epidermal growth factor receptor; ANOVA, analysis of variance.
Anti Ki67, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ki67/product/Danaher Inc
Average 95 stars, based on 1 article reviews
anti ki67 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
recombinant anti-ki67 antibody  (Advisains)
94
Advisains recombinant anti-ki67 antibody
Silencing of TRPM2-AS inhibited NSCLC progression in vivo. After injection with transfected A549 cells, the mice were observed every 5 days and sacrificed on day 30. (A) The tumors were harvested on day 30. (B) The tumor volume was measured and analyzed with one-way analysis of variance. (C) Relative TRPM2-AS and miR-138-5p expression in xenograft tumors was tested by qRT-PCR. (D) Expression levels of EGFR, <t>Ki67,</t> and TUNEL in the xenograft tumors were detected with immunohistochemistry under 200× scope (stained with diaminobenzidine). (E) Relative EGFR expression in the xenograft tumors. (F) Relative miR-138-5p expression in the xenograft tumors was tested by qRT-PCR. (G) Cell apoptosis in the xenograft tumors was tested with TUNEL assay. The staining was analyzed with Image Pro Plus. Data are shown as mean ± SD. *, P<0.05, **, P<0.01 versus control t-test or one-way ANOVA. NSCLC, non-small cell lung cancer; qRT-PCR, quantitative real-time polymerase chain reaction; EGFR, epidermal growth factor receptor; ANOVA, analysis of variance.
Recombinant Anti Ki67 Antibody, supplied by Advisains, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant anti-ki67 antibody/product/Advisains
Average 94 stars, based on 1 article reviews
recombinant anti-ki67 antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Silencing of TRPM2-AS inhibited NSCLC progression in vivo. After injection with transfected A549 cells, the mice were observed every 5 days and sacrificed on day 30. (A) The tumors were harvested on day 30. (B) The tumor volume was measured and analyzed with one-way analysis of variance. (C) Relative TRPM2-AS and miR-138-5p expression in xenograft tumors was tested by qRT-PCR. (D) Expression levels of EGFR, Ki67, and TUNEL in the xenograft tumors were detected with immunohistochemistry under 200× scope (stained with diaminobenzidine). (E) Relative EGFR expression in the xenograft tumors. (F) Relative miR-138-5p expression in the xenograft tumors was tested by qRT-PCR. (G) Cell apoptosis in the xenograft tumors was tested with TUNEL assay. The staining was analyzed with Image Pro Plus. Data are shown as mean ± SD. *, P<0.05, **, P<0.01 versus control t-test or one-way ANOVA. NSCLC, non-small cell lung cancer; qRT-PCR, quantitative real-time polymerase chain reaction; EGFR, epidermal growth factor receptor; ANOVA, analysis of variance.

Journal: Annals of Translational Medicine

Article Title: Long non-coding RNA TRPM2-AS sponges microRNA-138-5p to activate epidermal growth factor receptor and PI3K/AKT signaling in non-small cell lung cancer

doi: 10.21037/atm-20-6331

Figure Lengend Snippet: Silencing of TRPM2-AS inhibited NSCLC progression in vivo. After injection with transfected A549 cells, the mice were observed every 5 days and sacrificed on day 30. (A) The tumors were harvested on day 30. (B) The tumor volume was measured and analyzed with one-way analysis of variance. (C) Relative TRPM2-AS and miR-138-5p expression in xenograft tumors was tested by qRT-PCR. (D) Expression levels of EGFR, Ki67, and TUNEL in the xenograft tumors were detected with immunohistochemistry under 200× scope (stained with diaminobenzidine). (E) Relative EGFR expression in the xenograft tumors. (F) Relative miR-138-5p expression in the xenograft tumors was tested by qRT-PCR. (G) Cell apoptosis in the xenograft tumors was tested with TUNEL assay. The staining was analyzed with Image Pro Plus. Data are shown as mean ± SD. *, P<0.05, **, P<0.01 versus control t-test or one-way ANOVA. NSCLC, non-small cell lung cancer; qRT-PCR, quantitative real-time polymerase chain reaction; EGFR, epidermal growth factor receptor; ANOVA, analysis of variance.

Article Snippet: The following antibodies were used: anti-Ki67 (ab92742), anti-EGFR (ab52894), anti-PI3K (ab70912), anti-p-PI3K (ab182651), anti-AKT (ab8805), anti-p-AKT (ab38449), anti-mTOR (ab32028), anti-p-mTOR (ab137133), anti-GAPDH (ab181602), and Goat Anti-Rabbit (ab150077) (all purchased from Abcam, Cambridge, MA, USA).

Techniques: In Vivo, Injection, Transfection, Expressing, Quantitative RT-PCR, TUNEL Assay, Immunohistochemistry, Staining, Control, Real-time Polymerase Chain Reaction